Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

MAGIC Next-generation models and genetic therapies for rare neuromuscular diseases

Coordinator
Institut National De La Sante Et De La Recherche Medicale, France
Runs
1 June 2023 to 31 May 2027
Status
Running
EU funding
€6.6m
Total cost
€6.6m
Partners
19 organisations in 11 countries
Type
Research and Innovation Action
Grant agreement
101080690

What the project is doing

In the project's own words, from its summary on CORDIS.

Muscular dystrophies are severe genetic disorders characterised by muscle wasting, impaired mobility and premature death, which to date remain incurable. Although preclinical and clinical evidence position genetic therapies amongst the key emerging treatments for several genetic conditions, no gene therapy or genome editing strategy has been approved for any muscular dystrophies yet. The lack of robust, human(ised) models enabling precise development of such advanced therapies is a major barrier towards their clinical translation for muscle diseases.

To overcome this limitation, we have assembled the multidisciplinary MAGIC consortium to build novel, high-fidelity, models of human skeletal muscle pathophysiology which will be used to develop new vectors for safe and efficacious neuromuscular gene therapy and genome editing. Specific rare (paediatric) diseases targeted by our consortium are Duchenne muscular dystrophy (DMD), X-linked (XLCNM), autosomal dominant (ADCNM) and autosomal recessive (ARCNM) centronuclear myopathies (CNMs), LMNA- and COL6-related congenital muscular dystrophies (CMDs).

Microfabrication, microfluidics and human stem cell differentiation technologies will be used to generate disease-specific human myofiber- and muscle-on-chip devices qualified for commercialisation, capable of screening toxicity and cell-specificity of new adeno-associated viral vector (AAV) capsid variants, and unique muscle-specific lentiviruses. Selected vectors will be equipped with novel lineage-specific regulatory elements to further restrict transgene expression to myofibres, muscle stem cells or interstitial fibroblasts, reducing also potential immunogenicity.

The same vectors will be loaded with therapeutic genes or with new mutation-independent (for DMD and XLCNM) or mutation-specific (for LMNA- and COL6-CMD) gene editing tools, which will then be validated in dystrophic rodents. Finally, GMP-compatible batches of the top performing vectors will undergo advanced preclinical testing in large animals, preparing them for future clinical translation.

Topics

Who is involved

OrganisationCityCountryRole
Institut National De La Sante Et De La Recherche MedicaleParisFranceCoordinator
Siegfried Dinamiqs AGSchlierenSwitzerlandAssociatedpartner
Dinabios Deutschland GmbHHamburgGermanyAssociatedpartner
Medizinische Hochschule HannoverHannoverGermanyParticipant
Vivebiotech SLSan SebastianSpainParticipant
Universite Paris Xii Val De MarneCreteilFranceParticipant
National University of Ireland MaynoothMaynoothIrelandParticipant
Parent Project ApsRomaItalyParticipant
Reithera SRLRomaItalyParticipant
Biond Solutions BVDelftNetherlandsParticipant
Optics11 Life B.V.AmsterdamNetherlandsParticipant
Stichting Duchenne Data FoundationSoestNetherlandsParticipant
Fundacao Gimm - Gulbenkian Institute for Molecular MedicineLisboaPortugalParticipant
Regenmed Solutions ABStockholmSwedenParticipant
King's College LondonLondonUnited KingdomAssociatedpartner
Muscular Dystrophy Group of Great Britain and Northern IrelandLondonUnited KingdomAssociatedpartner
The Francis Crick Institute LimitedLondonUnited KingdomAssociatedpartner
University College LondonLondonUnited KingdomAssociatedpartner
Children's Hospital Medical CenterCincinnatiUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI